CN100345548C - 用于治疗骨折的药物 - Google Patents
用于治疗骨折的药物 Download PDFInfo
- Publication number
- CN100345548C CN100345548C CNB008117659A CN00811765A CN100345548C CN 100345548 C CN100345548 C CN 100345548C CN B008117659 A CNB008117659 A CN B008117659A CN 00811765 A CN00811765 A CN 00811765A CN 100345548 C CN100345548 C CN 100345548C
- Authority
- CN
- China
- Prior art keywords
- bone
- purposes
- medicine
- fracture
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 48
- 230000001737 promoting effect Effects 0.000 claims abstract description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 143
- 206010017076 Fracture Diseases 0.000 claims description 73
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 claims description 62
- 230000000638 stimulation Effects 0.000 claims description 36
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 34
- 230000011164 ossification Effects 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 9
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000004873 anchoring Methods 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010017081 Fracture delayed union Diseases 0.000 claims 1
- 206010027336 Menstruation delayed Diseases 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 230000002642 osteogeneic effect Effects 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract description 7
- 150000004663 bisphosphonates Chemical class 0.000 abstract description 6
- 230000008468 bone growth Effects 0.000 abstract description 3
- 208000010392 Bone Fractures Diseases 0.000 description 69
- 230000008929 regeneration Effects 0.000 description 61
- 238000011069 regeneration method Methods 0.000 description 61
- 210000002303 tibia Anatomy 0.000 description 56
- 241000283973 Oryctolagus cuniculus Species 0.000 description 30
- 229910052500 inorganic mineral Inorganic materials 0.000 description 30
- 239000011707 mineral Substances 0.000 description 30
- 210000003414 extremity Anatomy 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 238000011160 research Methods 0.000 description 16
- 238000005259 measurement Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 208000001132 Osteoporosis Diseases 0.000 description 11
- 230000002035 prolonged effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 210000003141 lower extremity Anatomy 0.000 description 10
- 210000000963 osteoblast Anatomy 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 210000002997 osteoclast Anatomy 0.000 description 8
- 206010020649 Hyperkeratosis Diseases 0.000 description 7
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 210000002414 leg Anatomy 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 230000003750 conditioning effect Effects 0.000 description 5
- 230000001582 osteoblastic effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000002601 radiography Methods 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 4
- 229960001736 buprenorphine Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 4
- 229950006971 incadronic acid Drugs 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000020431 spinal cord injury Diseases 0.000 description 4
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
- 229960001600 xylazine Drugs 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 229940001490 fosamax Drugs 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010231 histologic analysis Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000009940 knitting Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 238000009101 premedication Methods 0.000 description 3
- 238000011555 rabbit model Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010049811 Extraskeletal ossification Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000034970 Heterotopic Ossification Diseases 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 229940089617 risedronate Drugs 0.000 description 2
- 239000010907 stover Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940019375 tiludronate Drugs 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 208000037848 Metastatic bone disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000002565 Open Fractures Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- -1 bisphosphonate etidronate Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000003364 bony callus Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000450 navicular bone Anatomy 0.000 description 1
- 201000000173 nephrocalcinosis Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004345 peroneal nerve Anatomy 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ2325 | 1999-08-19 | ||
| AUPQ2325A AUPQ232599A0 (en) | 1999-08-19 | 1999-08-19 | Drug for treating fractures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1370071A CN1370071A (zh) | 2002-09-18 |
| CN100345548C true CN100345548C (zh) | 2007-10-31 |
Family
ID=3816500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008117659A Expired - Fee Related CN100345548C (zh) | 1999-08-19 | 2000-08-17 | 用于治疗骨折的药物 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1214079A4 (no) |
| JP (1) | JP2003507426A (no) |
| KR (1) | KR20020027562A (no) |
| CN (1) | CN100345548C (no) |
| AU (1) | AUPQ232599A0 (no) |
| BR (1) | BR0013416A (no) |
| CA (1) | CA2381302A1 (no) |
| HK (1) | HK1048441B (no) |
| HU (1) | HUP0202396A3 (no) |
| IL (1) | IL148166A0 (no) |
| NO (1) | NO20020784L (no) |
| NZ (1) | NZ517538A (no) |
| PL (1) | PL353485A1 (no) |
| SK (1) | SK2382002A3 (no) |
| WO (1) | WO2001013922A1 (no) |
| ZA (1) | ZA200202160B (no) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ527351A (en) | 2001-02-06 | 2005-01-28 | Royal Alexandra Hosp Children | Use of bisphosphonate for the treatment of osteonecrosis and for the management of patients at risk of developing ostenonecrosis |
| WO2002080933A1 (en) * | 2001-04-03 | 2002-10-17 | The Royal Alexandra Hospital For Children | A drug for use in bone grafting |
| AUPR553701A0 (en) * | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
| EP1508343B1 (en) * | 2003-08-21 | 2015-11-04 | AddBIO AB | Bisphosponate coated implant device and method therefor |
| RU2326695C2 (ru) * | 2003-09-19 | 2008-06-20 | Пфайзер Продактс Инк. | Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната |
| ITMI20040218A1 (it) * | 2004-02-10 | 2004-05-10 | Abiogen Pharma Spa | Uso di neridronato sodico per promuovere la neoformazione ossea |
| ITMI20040641A1 (it) * | 2004-03-31 | 2004-06-30 | Tb Technology S R L | Composizioni bioadesive bifunzionali per implantologia orale |
| AR048742A1 (es) * | 2004-12-22 | 2006-05-24 | Gador Sa | Sistema de aplicacion de medicamentos intra-oral |
| JP5426168B2 (ja) * | 2005-10-27 | 2014-02-26 | トーメン メディカル アーゲー | 歯科インプラント及びその製造方法 |
| US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021266A1 (en) * | 1993-03-24 | 1994-09-29 | Leiras Oy | The use of bisphosphonates in bone surgery |
| CN1146152A (zh) * | 1994-04-21 | 1997-03-26 | 麦克公司 | 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用 |
| US5616560A (en) * | 1991-12-17 | 1997-04-01 | The Procter & Gamble Company | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone |
| US5853759A (en) * | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
| CN1226253A (zh) * | 1996-06-28 | 1999-08-18 | 利物浦大学 | 甾体二膦酸酯 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8107560A (pt) * | 1981-11-19 | 1983-07-05 | Luiz Romariz Duarte | Estimulacao ultra-sonica da consolidacao de fraturas osseas |
| AU670337B2 (en) * | 1992-11-30 | 1996-07-11 | Novartis Ag | Use of certain methanebisphosphonic acid derivatives in fracture healing |
| EP0600834A1 (en) * | 1992-11-30 | 1994-06-08 | Ciba-Geigy Ag | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing |
| AU5953894A (en) * | 1992-12-23 | 1994-07-19 | Merck & Co., Inc. | Bisphosphonate/estrogen therapy for treating and preventing bone loss |
| GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
| US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
| AU703887B2 (en) * | 1995-06-06 | 1999-04-01 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
-
1999
- 1999-08-19 AU AUPQ2325A patent/AUPQ232599A0/en not_active Abandoned
-
2000
- 2000-08-17 BR BR0013416-3A patent/BR0013416A/pt not_active Application Discontinuation
- 2000-08-17 HU HU0202396A patent/HUP0202396A3/hu unknown
- 2000-08-17 CN CNB008117659A patent/CN100345548C/zh not_active Expired - Fee Related
- 2000-08-17 EP EP00952791A patent/EP1214079A4/en not_active Withdrawn
- 2000-08-17 SK SK238-2002A patent/SK2382002A3/sk not_active Application Discontinuation
- 2000-08-17 CA CA002381302A patent/CA2381302A1/en not_active Abandoned
- 2000-08-17 KR KR1020027002160A patent/KR20020027562A/ko not_active Application Discontinuation
- 2000-08-17 PL PL00353485A patent/PL353485A1/xx not_active Application Discontinuation
- 2000-08-17 WO PCT/AU2000/000982 patent/WO2001013922A1/en active IP Right Grant
- 2000-08-17 JP JP2001518059A patent/JP2003507426A/ja active Pending
- 2000-08-17 NZ NZ517538A patent/NZ517538A/en unknown
- 2000-08-17 IL IL14816600A patent/IL148166A0/xx unknown
-
2002
- 2002-02-18 NO NO20020784A patent/NO20020784L/no not_active Application Discontinuation
- 2002-03-15 ZA ZA200202160A patent/ZA200202160B/en unknown
-
2003
- 2003-01-21 HK HK03100502.8A patent/HK1048441B/zh not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616560A (en) * | 1991-12-17 | 1997-04-01 | The Procter & Gamble Company | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone |
| WO1994021266A1 (en) * | 1993-03-24 | 1994-09-29 | Leiras Oy | The use of bisphosphonates in bone surgery |
| CN1146152A (zh) * | 1994-04-21 | 1997-03-26 | 麦克公司 | 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用 |
| US5853759A (en) * | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
| CN1226253A (zh) * | 1996-06-28 | 1999-08-18 | 利物浦大学 | 甾体二膦酸酯 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200202160B (en) | 2003-08-27 |
| PL353485A1 (en) | 2003-11-17 |
| WO2001013922A1 (en) | 2001-03-01 |
| HK1048441B (zh) | 2008-02-22 |
| HUP0202396A3 (en) | 2005-02-28 |
| EP1214079A1 (en) | 2002-06-19 |
| KR20020027562A (ko) | 2002-04-13 |
| CN1370071A (zh) | 2002-09-18 |
| SK2382002A3 (en) | 2002-09-10 |
| NZ517538A (en) | 2003-07-25 |
| CA2381302A1 (en) | 2001-03-01 |
| AUPQ232599A0 (en) | 1999-09-09 |
| NO20020784D0 (no) | 2002-02-18 |
| IL148166A0 (en) | 2002-09-12 |
| HK1048441A1 (en) | 2003-04-04 |
| BR0013416A (pt) | 2002-04-30 |
| JP2003507426A (ja) | 2003-02-25 |
| HUP0202396A2 (hu) | 2002-11-28 |
| NO20020784L (no) | 2002-02-18 |
| EP1214079A4 (en) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cassetta et al. | Depth deviation and occurrence of early surgical complications or unexpected events using a single stereolithographic surgi-guide | |
| CN100345548C (zh) | 用于治疗骨折的药物 | |
| Philippe | Custom-made prefabricated titanium miniplates in Le Fort I osteotomies: principles, procedure and clinical insights | |
| CN1308545A (zh) | 增加骨的韧性和劲度以及减少骨折的方法 | |
| Ochi et al. | Factors affecting accuracy of implant placement with mucosa-supported stereolithographic surgical guides in edentulous mandibles | |
| CN1976726A (zh) | 用于调节骨量的组合物和方法 | |
| Little et al. | Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis: A study in immature rabbits | |
| Allen et al. | Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone | |
| Rego et al. | Suppl 1: Current status of low intensity pulsed ultrasound for dental purposes | |
| JP2022064986A (ja) | Ｌｌｐ２ａ－ビスホスホネート化合物を用いて骨壊死を処置する方法 | |
| Bosshard et al. | Accuracy of augmented reality-assisted vs template-guided apicoectomy—An ex vivo comparative study | |
| Zacchetti et al. | External mechanical microstimuli modulate the osseointegration of titanium implants in rat tibiae | |
| Yu et al. | Effects of bisphosphonates on osseointegration of dental implants in rabbit model | |
| Arimoto et al. | Effect of low-intensity pulsed ultrasound after intraoral vertical ramus osteotomy | |
| Dominiak et al. | Three-dimensional bone block planning for mandibular sagittal bone defect reconstruction | |
| Sasaki et al. | Effect of low-intensity pulsed ultrasound (LIPUS) on mandibular condyle growth in rats analyzed with micro-CT | |
| Druelle et al. | A modified method for a customized harvest of fibula free flap in maxillofacial reconstruction | |
| RU2651363C1 (ru) | Способ остеосинтеза перелома нижней челюсти с одновременным устранением адентии | |
| TW201302164A (zh) | 口顎影像融合方法 | |
| Saghieh et al. | The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study | |
| 고창용 | Non-pharmacological therapies using biophysical stimuli for treatment and prevention of osteoporosis | |
| Fu et al. | Accuracy and patient-centered results of static and dynamic computer-assisted implant surgery in edentulous jaws: a retrospective cohort study | |
| Amuk et al. | Effects of orofacial applications of low-magnitude, high-frequency mechanical vibration on cranial sutures and calvarial bones: A micro-computed tomography study in rats | |
| Miyabe et al. | Accelerated fracture healing using low-intensity pulsed ultrasound in an aged rat closed femoral fracture model | |
| Aizenberg et al. | Short-term postoperative discomfort in patients receiving flapless contra open implant surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1048441 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071031 Termination date: 20090817 |